Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18582398rdf:typepubmed:Citationlld:pubmed
pubmed-article:18582398lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18582398lifeskim:mentionsumls-concept:C0947647lld:lifeskim
pubmed-article:18582398lifeskim:mentionsumls-concept:C1515144lld:lifeskim
pubmed-article:18582398lifeskim:mentionsumls-concept:C0439662lld:lifeskim
pubmed-article:18582398pubmed:issue3lld:pubmed
pubmed-article:18582398pubmed:dateCreated2008-6-27lld:pubmed
pubmed-article:18582398pubmed:abstractTextAdoptive immunotherapy involving the transfer of autologous tumor or virus-reactive T lymphocytes has been demonstrated to be effective in the eradication of cancer and virally infected cells. Identification of MHC-restricted antigens and progress in generation of adaptive immune responses have provided new direction for such treatment for severe pathologies such as cancer and autoimmune diseases. Here we review the latest development about the molecular basis of MHC-I/TCR interaction, and its manipulation including enhanced MHC-I expression, modification of peptide and engineered TCR for clinical applications such as vaccine design, tumor therapy and autoimmune diseases.lld:pubmed
pubmed-article:18582398pubmed:languageenglld:pubmed
pubmed-article:18582398pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18582398pubmed:citationSubsetIMlld:pubmed
pubmed-article:18582398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18582398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18582398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18582398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18582398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18582398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18582398pubmed:statusMEDLINElld:pubmed
pubmed-article:18582398pubmed:monthJunlld:pubmed
pubmed-article:18582398pubmed:issn1672-7681lld:pubmed
pubmed-article:18582398pubmed:authorpubmed-author:LeeS KSKlld:pubmed
pubmed-article:18582398pubmed:authorpubmed-author:LiuQing JunQJlld:pubmed
pubmed-article:18582398pubmed:issnTypePrintlld:pubmed
pubmed-article:18582398pubmed:volume5lld:pubmed
pubmed-article:18582398pubmed:ownerNLMlld:pubmed
pubmed-article:18582398pubmed:authorsCompleteYlld:pubmed
pubmed-article:18582398pubmed:pagination171-82lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:meshHeadingpubmed-meshheading:18582398...lld:pubmed
pubmed-article:18582398pubmed:year2008lld:pubmed
pubmed-article:18582398pubmed:articleTitleManipulation of MHC-I/TCR interaction for immune therapy.lld:pubmed
pubmed-article:18582398pubmed:affiliationInstitute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.lld:pubmed
pubmed-article:18582398pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18582398pubmed:publicationTypeReviewlld:pubmed